MobiHealthNews

Dexcom CEO tells investors not to fear new competition from Abbott's Freestyle Libre

Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
The Motley Fool

Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?

Abbott and DexCom depend heavily on continuous glucose monitoring (CGM) device sales. Vertex is developing therapies that could cure type 1 diabetes. If Vertex is successful, the CGM market could be ...
The Motley Fool

Is Beaten-Down Dexcom Stock a Buy on the Dip?

Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device. Dexcom's main ...
MobiHealthNews

Insulet's Omnipod to integrate with Dexcom, Abbott CGMs for automated, smartphone-controlled dosing

Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated ...
Seeking Alpha

DexCom: Riding The Growth Wave

DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the ...